Now is Our Opportunity to Revolutionise Cancer Clinical Trials
Authors:
- 18 November 2022
- journal article
- editorial
- Published by Elsevier in Clinical Oncology
- Vol. 35 (3) , 139-142
Abstract
No abstract availableFunding Information
- Cancer Research UK
- Yorkshire Cancer Research
- National Institute for Health and Care Research
This publication has 5 references indexed in Scilit:
- Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N TrialJournal of Clinical Oncology, 2021
- Evolution of the Randomized Clinical Trial in the Era of Precision OncologyJAMA Oncology, 2021
- Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialPLOS Medicine, 2021
- Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysisBMJ, 2018
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNew England Journal of Medicine, 2017